QDEL

QuidelOrtho's stock price has experienced significant declines in the past six months. Preliminary Q1 2026 revenue guidance led to a 21% drop in shares due to a weaker respiratory season, slower distributor sales in China, and delayed EMEA orders. The company reported a quarterly loss of ($0.04) EPS, missing analyst consensus, and revenue of $619.8 million, below expectations. QuidelOrtho updated its full-year 2026 earnings guidance, expecting total revenues in the range of $2.7 billion - $2.75 billion. The company announced plans to discontinue the development of its Savanna platform and completed the acquisition of the remaining majority stake in Lex Diagnostics Limited from TTP Group.